

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

THIS ANNOUNCEMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.



Hilong Holding Limited
海隆控股有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1623)

**ANNOUNCEMENT REGARDING EXTENSION OF EXPIRATION TIME
OF CONSENT SOLICITATION RELATING TO ITS:**

9.75% Senior Secured Notes Due 2024

(Regulation S Notes: ISIN XS2344083139/Common Code 234408313
Rule 144A Notes: ISIN XS2344082917/Common Code 234408291
IAI Notes: ISIN XS2344083303/Common Code 234408330)

This announcement is made by Hilong Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 30 October 2024, 18 November 2024, 30 December 2024, 30 March 2025, 31 March 2025, 30 June 2025, 31 October 2025, 11 December 2025 and 13 January 2026, and the 2023 annual report published on 28 November 2024, the 2024 interim report published on 16 December 2024, the 2024 annual report published on 29 April 2025, and the 2025 interim report published on 29 September 2025, in relation to, among other things, the proposed offshore debt restructuring of its 9.75% Senior Secured Notes due 2024 (the “**Existing Notes**”). Terms used but not otherwise defined in this announcement shall have the meaning assigned to them in the Consent Solicitation Statement (as defined below), which is available, subject to eligibility and registration, on the Transaction Website: <https://projects.sodali.com/hilong>.

The Company announces that, in connection with its previously announced consent solicitation (the “**Consent Solicitation**”) launched pursuant to the consent solicitation statement dated as of 11 December 2025 (the “**Consent Solicitation Statement**”), the Expiration Time (as defined in the Consent Solicitation Statement) is hereby further extended from 4:00 p.m., London time, on 22 January 2026 to **4:00 p.m., London time, on 28 January 2026**.

Holders who have previously submitted their instructions with respect to the Consent Solicitation do not have to undertake any further action.

The above times and dates are subject to the right of the Company to extend, re-open, amend and/or terminate the Consent Solicitation (including the timing of the Expiration Time) in accordance with the terms of applicable law, the Existing Indenture and/or as provided in the Consent Solicitation Statement.

Eligibility to Participate. The Consent Solicitation is directed only to those Holders who are either (1)(A) “qualified institutional buyers” (as that term is defined in Rule 144A under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”)), or (B) “institutional accredited investors” (within the meaning of Rule 501(a)(1), (2), (3), (7), (8), (9), (12) or (13), under the U.S. Securities Act), in each case, transacting in a private transaction in reliance upon an exemption from the registration requirements of the U.S. Securities Act, or (2) persons that are outside the United States transacting in an offshore transaction in accordance with Regulation S under the U.S. Securities Act (each such Holder, an “**Eligible Holder**”). Only Holders of Existing Notes who have certified that they are Eligible Holders are authorized to receive and review the Consent Solicitation Statement and to participate in the Consent Solicitation.

Additional Information

The Company has retained Sodali & Co. Limited as the Information and Tabulation Agent in connection with the Consent Solicitation. The Consent Solicitation Statement and other documents relevant to the Consent Solicitation have been made available to all Eligible Holders through the Information and Tabulation Agent and at its website set out below:

Sodali & Co. Limited

Email: hilong@investor.sodali.com

Transaction Website: <https://projects.sodali.com/hilong>

In London

The Leadenhall Building
122 Leadenhall Street
London EC3V 4AB
Telephone No.: +44 20 4513 6933

In Hong Kong

1401, 14/F
90 Connaught Road Central
Sheung Wan, Hong Kong
Telephone No.: +852 2319 4130

If you have any questions about the Consent Solicitation, you should contact the Information and Tabulation Agent.

Admiralty Harbour Capital Limited acts as financial adviser to the Company. Kirkland & Ellis International LLP acts as legal adviser to the Company.

Important Notice

This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Existing Notes or any other security in any jurisdiction and shall, in any circumstance, not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful. The Existing Notes have not been and will not be registered under the U.S. Securities Act or with any securities regulatory authority of any state or other jurisdiction of the United States or in any other jurisdiction.

The Consent Solicitation is directed only to those Holders who are Eligible Holders.

For and on behalf of the Board
Hilong Holding Limited
ZHANG Jun
Chairman

Hong Kong, 23 January 2026

As at the date of this announcement, the executive director of the Company is Mr. ZHANG Jun; the non-executive directors are Ms. ZHANG Shuman, Dr. YANG Qingli, Mr. CAO Hongbo and Dr. FAN Ren Da Anthony; and the independent non-executive directors are Mr. WANG Tao, Mr. WONG Man Chung Francis, Mr. SHI Zheyuan and Mr. YAN Jiantao.

* For identification purposes only.